Abstract 446P
Background
Patients with cancer often develop cachexia. There has been no clearly effective treatment for this condition. However, anamorelin is approved for the treatment of cancer cachexia associated with advanced non-small cell lung cancer.
Methods
We conducted a retrospective analysis of treatment efficacy, adverse events and background factors in non-small cell lung cancer patients treated with anamorelin for cancer cachexia at our hospital from 1 April 2021 to 30 April 2023. Anamorelin effective cases were defined as those with improved performance status (PS) or appetite.
Results
A total of 68 patients were treated with anamorelin during the study period. The median age was 76.5 (59-92) years and the male patients were predominantly. Comorbidities included COPD (29.4%), interstitial pneumonia (22.1%). The clinical stage of lung cancer was stage 4 in 75.7% of patients. The median duration of anamorelin treatment was 36 (1-714) days. Anamorelin improved anorexia in 32 patients and PS in 21 patients. According to the definition of our study, there were 34 patients with anamorelin response and 34 patients without response. The patients with anamorelin response had a significantly longer duration of treatment (P<0.01) and significantly lower C-reactive protein (CRP) before treatment (P=0.04) compared to the patients without anamorelin response. The most common adverse events were nausea (14.7%), appetite loss (13.2%), hyperglycemia (11.8%) and liver damage (10.3%), respectively. Three patients experienced G3≤ adverse events. Fourteen (20.6%) patients discontinued anamorelin due to adverse events. The frequency of adverse events did not differ between the two groups.
Conclusions
Anamorelin improved appetite or PS in half of the patients in this retrospective study. In contrast, 14 (20.6 %) patients discontinued treatment due to adverse events. Anamorelin may be more effective in patients with lower CRP levels prior to treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T. Ito.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract